Aspen H1’25 HEPS up 4%
Shares of Aspen jumped more than 11 per cent on the JSE today, narrowing losses in the stock in the past year to 16 per cent. Africa’s largest pharmaceutical group reported a 5 per cent increase in normalized HEPS for the six months to December but guided for double digit growth in revenue and core profit from its commercial pharmaceuticals unit in the full-year, benefiting from its Latin American portfolio and Mounjaro rollout. CNBC Africa is joined by Stephen Saad, CEO, Aspen Group for more.
Mon, 03 Mar 2025 15:23:13 GMT
Disclaimer: The following content is generated automatically by a GPT AI and may not be accurate. To verify the details, please watch the video
AI Generated Summary
- Aspen's strong stock performance on the JSE highlighted by a 11 per cent increase, narrowing past year losses
- Operational successes during the interim period, with EBITDA up over 20 per cent, offset by currency fluctuations impacting reported earnings
- Discussion on Manjaro rollout success in South Africa, partnerships, and the potential impact of global geopolitical shifts on Aspen's business strategy
Shares of Aspen, Africa's largest pharmaceutical group, soared over 11 per cent on the JSE, marking a significant rebound from past year losses. The company reported a 5 per cent increase in normalized HEPS for the six months to December. Aspen's CEO, Stephen Saad, highlighted the operational successes during the period, with EBITDA up over 20 per cent and growth across both business segments. However, currency fluctuations, particularly the strength of the Rand, impacted reported earnings. Saad emphasized the challenges posed by the strong Rand but remained positive about the company's performance given the current economic sentiment in South Africa. The interview also touched on Aspen's resilience amidst adverse weather events, with a focus on climate change risk management. The discussion shifted to Aspen's growth prospects, notably the successful Manjaro rollout in South Africa, which garnered a 20 percent market share before its official launch. Saad expressed confidence in the product's potential, citing its impact on the private market. The conversation also delved into Aspen's partnerships and the potential impact of global geopolitical shifts on the pharmaceutical industry. Saad emphasized the need to adapt to evolving dynamics and focus on present actions rather than long-term predictions.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.
